Research Article
PTB Reports
Analysis of Gabapentinoids Abuse-Reports in the Middle East
and North Africa Region Utilizing the Food and Drug
Administration Adverse Event Reporting System
Mona Yaser Alsheikh, College of
Pharmacy, Taif University, Taif, SAUDI
ARABIA.
Ali Mofleh Alshahrani, College of
Pharmacy, Taif University, Taif, SAUDI
ARABIA.
Reem Dhayan Almutairi, Department
of Pharmaceutical Business and
Administrative Sciences, MCPHS
University, Boston, MA, USA.
Hana Abdulmohsen Althobaiti, College
of Pharmacy, Chapman University, Irvine,
California, US.
Ahmed Ibrahim Fathelrahman, College
of Pharmacy, Taif University, Taif, SAUDI
ARABIA.
Enrique Seoane-Vazquez, College of
Pharmacy, Chapman University, Irvine,
California, US.
Moudi Mubarak Alasmari*, 1College
of Medicine, King Saud bin Abdulaziz
University for Health Sciences (KSAU-HS),
Jeddah, SAUDI ARABIA.
2
King Abdullah International Medical
Research Center (KAIMRC), Jeddah, SAUDI
ARABIA.
ABSTRACT
Objectives: The purpose of this study was to identify abuse-related post-marketing reports associated
with gabapentinoids use in the Middle East and North Africa (MENA) region countries. Methods: A
retrospective cross-sectional analysis of abuse-related adverse drug event (ADE) reports from the
Middle East and North Africa (MENA) region. It was performed using the Food and Drug Administration
Adverse Event Reporting System (FAERS) database from January 2008 through June 2020. Abuserelated ADE reports for gabapentin and pregabalin were extracted from the FAERS database.
Descriptive statistics were performed, and the proportional reporting ratio (PRR) was calculated to
detect disproportional attribution of abuse-related ADEs for gabapentin versus pregabalin. Results:
We identified 559 all-cause ADE reports for gabapentinoids, including 205 (36.7%) abuse-related ADE
reports reported to FAERS in the period of analysis. FAERS included 139 (67.8%) pregabalin and 66
(32.2%) gabapentin abuse-related ADE reports. Among MENA region countries, Turkey (55, 39.6%)
and Saudi Arabia (34, 23.7%) had the highest number of abuse-related ADE reports for pregabalin.
The most pregabalin abuse-related ADE reports involved adult male patients. The PRR of pregabalin
versus gabapentin abuse-related ADE reports was 1.11, indicating that the number of abuse-related
events was higher for pregabalin compared to gabapentin. Conclusion: Over 200 cases of abuserelated gabapentinoids events were reported to FEARS from the MENA region in the study period.
Further studies should assess risk factors and potential programs to reduce gabapentinoids abuse.
Key words: Gabapentin, Pregabalin, Adverse drug events, MENA, FAERS, Abuse.
INTRODUCTION
Correspondence:
Dr. Moudi M Alasmari, Pharm D, MSc
College of Medicine, King Saud bin
Abdulaziz University for Health Sciences,
P.O Box 9515, Zip Code 21423, Jeddah,
SAUDI ARABIA.
Phone no: 00966 12 2245000
E-mail: alasmari_moudi@gmail.com
Received: 21-10-2020;
Accepted: 05-02-2021.
Copyright: © the author(s),publisher and licensee
Pharmacology, Toxicology and Biomedical Reports.
This is an open-access article distributed under the
terms of the Creative Commons Attribution NonCommercial License, which permits unrestricted
non-commercial use, distribution, and reproduction
in any medium, provided the original work is
properly cited.
This is an open access article distributed under
the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License
Access this article online
WWW.ptbreports.org
DOI:
10.5530/PTB.2021.7.2
PTB Reports, Vol 7, Issue 1, Jan-Apr, 2021
Gabapentinoids (pregabalin and gabapentin) are
widely prescribed in neurology and psychiatry
and often prescribed off-label for a range of
clinical conditions, including alcohol and
narcotic withdrawal states, non-neuropathic
pain disorders, and attention deficit hyperactivity
disorder. Gabapentinoids act as gammaaminobutyric acid (GABA) analogs, blocking
alpha-2- delta subunit-containing voltagedependent calcium channels.1 Gabapentin was
approved by the Food and Drug Administration
(FDA) for post-herpetic neuralgia and epilepsy
in 1993. Pregabalin was approved in 2004 for
neuropathic pain, fibromyalgia, post-herpetic
neuralgia, and seizures.2-5 In the United States, the
prescription rates for gabapentinoids increased
significantly between 2002 and 2015 and
pregabalin was a top 10 best-selling medication
in 2017.6,7 In Saudi Arabia, pregabalin was one of
the top 10 sold drugs during 2010-2015.8
Recent
systematic
reviews
documented
gabapentinoid abuse-related adverse drug
events (ADEs), including abuse, misuse,
dependence, or overdose.9,10 Studies have also
shown gabapentinoids are likely to be abused
among individuals with opioid dependence
syndrome.11-13 The abuse potential of
gabapentinoids has been demonstrated in some
clinical studies.9,10 In Saudi Arabia, a study found
that 12.4% of participants used pregabalin without
a prescription.14 Additionally, studies showed
the potential risks for pregabalin misuse, abuse,
and related harms in the United Arab Emirates
and Jordan.15,16 A few case reports also described
pregabalin abuse in Turkey and Lebanon.17-19
The abuse of gabapentinoids is a serious public
health problem.6,13,14,16-20 There are some differences
among countries in terms of gabapentinoids
scheduling system. According to the United
States Drug Enforcement Administration (DEA),
pregabalin is classified as a Schedule V controlled
substance, representing the least potential for
abuse. In contrast, gabapentin is not classified
as a controlled substance despite the evidence
of abuse.4,5,13 On the other hand, In Saudi
Arabia, in May 2015, pregabalin was classified
as a controlled substance by (SFDA). However,
gabapentin is still a prescribed medication (Saudi
Food and Drug Authority). The Jordan Food
and Drug Administration (JFDA) also included
pregabalin preparations in the restricted drug list
in 2017.21-23 On the other hand, gabapentinoids
are not controlled medications in Turkey.17
Although gabapentinoids share many similar
pharmacologic properties, such as interacting
with the same binding site, renal excretion,
comparable metabolic profiles, minimal
protein binding, and negligible drug-drug
interactions, they have significant absorption
differences.24-27 Gabapentin is absorbed less
rapidly than pregabalin, with maximum plasma
concentrations attained within 3-4 hr instead of 1
5
Alsheikh MY, et al.: Analysis of Gabapentinoids Abuse-Reports in the Middle East and North Africa Region
hr. Due to saturable absorption, gabapentin absorption drops from 68%
to 36% after the dosage increases from 300mg to 1600 mg. In contrast,
pregabalin’s absolute bioavailability maintains ≥90% despite increasing
doses.24,26,28 That might explain why pregabalin is classified as a controlled
medication while gabapentin is not.
A recent study, which used the United States data from the 2012-2016
Food and Drug Administration Adverse Event Reporting System
(FAERS) data; found that a total of 576 cases out of 10,038 (5.7%) abuserelated events were reported to FAERS for gabapentin, and 58 cases out
of 571 (10.2%) ADEs related to abuse were identified for pregabalin.29
This study has been conducted to evaluate epidemiological information
regarding the scope of gabapentinoids abuse utilizing the FAERS
database not to assess their abuse trends. To the authors’ knowledge, there
were no studies available at the time of this study that have identified
abuse-related post-marketing reports associated with gabapentinoids
(gabapentin and pregabalin) use in the Middle East and North Africa
(MENA) region countries.This study aimed to identify abuse-related
post-marketing reports associated with gabapentinoids (gabapentin and
pregabalin) use in the MENA region countries reported to FAERS from
January 2008 to June 2020.
MATERIALS AND METHODS
Data sources
A retrospective analysis of gabapentinoids (gabapentin and pregabalin)
ADE reports from the MENA region was performed using the FAERS
(U.S. Food and Drug Administration). The FAERS database contains
ADE reports, medication error reports, and product quality complaints
resulting in adverse events submitted to the FDA. The database is
designed to support the FDA’s post-marketing safety surveillance
program for drug and therapeutic biological products. In other words,
FAERS data play a significant role in identifying early safety signals.30-32
The dataset is publicly available online and de-identified on the FDA
website. Thus, no institutional review board approval is required. All
ADE reports for pregabalin and gabapentin reported to FAERS from
January 2008 to June 2020 were identified by searching the active
ingredient names, dosage forms, and spellings with no specific reaction
or outcome criteria.
The MENA region definition includes 23 countries: Afghanistan,
Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait,
Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Qatar, Saudi
Arabia, Somalia, Sudan, Syria, Tunisia, Turkey, United Arab Emirates,
Yemen. The MENA region reports were extracted by using International
Organization for Standardization (ISO) 3166-1 alpha-2 codes.33-35
FAERS classifies the reports expedited (reports from the manufacturer
submitted to the FDA within 15 days of a serious and unexpected ADE
not included in product labeling) and non-expedited reports of serious
and non-serious adverse events for new molecular entity (NME) products
within the first three years following FDA approval.36 Serious outcomes
include death, hospitalization, life-threatening, disability, congenital
anomaly, and/or other serious outcomes. The primary sources of FAERS
reports are categorized into healthcare professionals and consumers.
Abuse-related ADE reports were defined as reports with drug abuse, drug
dependence, drug tolerance, withdrawal syndrome, euphoric mood,
overdose, intentional overdose, intentional product misuse, product use
in unapproved indication, maternal use an illicit drug, loss of personal
independence in daily activities, substance-induced psychotic disorder,
and intoxication.25,29,37-39 The demographic characteristics of FAERS
reports are limited. ADE reports were classified by patient gender (male,
female) and age in years at the time of the report.
Data analysisDescriptive statistics were performed, and the proportional
reporting ratio (PRR) was calculated to detect a disproportional
6
attribution of ADEs for gabapentin versus pregabalin. The PRR was
calculated using the following equation: PRR=[Pa/Pt]/[Ga/Gt], where Pa =
number of ADEs reported for pregabalin abuse, Pt = total number of ADEs
reported for all pregabalin, Ga = number of ADEs reported of gabapentin
abuse, and Gt = total number of ADEs reported for all gabapentin. The
null value for a PRR is one, which means the higher the PRR, the greater
the strength of the signal of abuse.29,40 Descriptive statistical analyses,
including frequencies and percentages, were performed using Microsoft
Excel (2016 Version, Redmond, WA).
RESULTS
We identified 559 all-cause FAERS ADE reports for gabapentinoids from
January 2008 to June 2020, including 366 (65.5%) pregabalin and 193
(34.5%) gabapentin reports.
FAERS listed 66 (32.2%) abuse-related gabapentin ADE reports, of
which 55 (83.3%) were reported by healthcare professionals, and 63
(95.5%) were expedited reports. There were 35 (53.0%) abuse-related
ADEs reports of women patients. The mean patient age among abuserelated ADEs was 54.4±16.5 years (median=50). Among MENA region
countries, Turkey (42, 63.6% of all MENA reports) had the greatest
number of reports, followed by Iran (17, 25.8%) (Table 1).
The most common gabapentin abuse-related ADEs reactions were
for indications that are non-FDA approved, which were mentioned in
16 (23.2%) reports (Table 2). Other gabapentin abuse-related ADEs
included 15 (21.7%) substance-induced psychotic disorder, 14 (20.3%)
intoxication, 8 (11.6%) withdrawal syndrome and 8 (11.6%) maternal
use of illicit drugs reactions. The outcomes reported for gabapentin
abuse-related ADE included 6 (9.1%) death, 8 (12.1%) hospitalizations,
and 46 (69.7%) other serious outcomes (Table 3).
Moreover, from January 2008 to June 2020, FAERS listed 139 (67.8%)
abuse-related pregabalin ADE reports. There were 106 (76.3%) cases
were reported by healthcare professionals to the FAERS database, and
137 (98.6%) were expedited reports. There were 67 (48.2%) abuse-related
ADEs reports of male patients. The mean patient age among abuserelated ADEs was (36.0 ± 19.1) years (median=28). Among MENA
region countries, Turkey (55, 39.6%) had the greatest number of reports,
followed by Saudi Arabia (34, 23.7%) and Jordan (19, 13.7%) (Table 1).
Drug abuse was mentioned in 77 (39.1%) reports and was the most
frequent pregabalin abuse-related ADE, followed by overdose (24,
12.2%), intentional overdose (12, 6.1%), and drug dependence reactions
(12, 6.1%) (Table 2). The outcomes reported for pregabalin abuse-related
ADE included 4 (2.9%) death, 24 (17.3%) hospitalizations, 2 (1.4%)
congenital anomalies, and 103 (74.1%) other serious outcomes (Table 3).
The PRR of pregabalin versus gabapentin abuse-related events was 1.11,
indicating that the number of abuse-related ADEs and the strength of the
signal of abuse were slightly higher for pregabalin than for gabapentin.
DISCUSSION
This study’s results indicate that most of the gabapentinoids abuserelated events reported in some of the MENA region countries in the
study period were associated with pregabalin use. This finding could
be due to the distinct pharmacokinetic advantages of pregabalin over
gabapentin. These advantages have been linked to the superiority of
pregabalin pharmacodynamic properties such as higher bioavailability,
faster absorption, and rapid onset of action with higher potency than
gabapentin, which may explain the higher addiction potential of
pregabalin.24-28We also noted that Turkey, Saudi Arabia, and Jordan
had the greatest number of pregabalin abuse-related ADE reports
among MENA region countries. In most MENA region countries,
gabapentinoids are prescribed as non-controlled medications.16,41
However, some of the MENA countries have taken serious actions to
PTB Reports, Vol 7, Issue 1, Jan-Apr, 2021
Alsheikh MY, et al.: Analysis of Gabapentinoids Abuse-Reports in the Middle East and North Africa Region
prevent the risk of gabapentinoids abuse. For instance, in Saudi Arabia,
the SFDA classified pregabalin as a controlled substance in May 2015, but
gabapentin has not been classified as a controlled substance yet (Saudi
Food and Drug Authority). In Jordan, the JFDA added pregabalin to the
restricted drug list in 2017.21-23Previous studies show that gabapentinoid
abuse events seem to be more likely in young adults; however, data about
gender differences are conflicting.10,29,39 Our study found that most of the
gabapentin abuse-related ADE reports involved adult women patients,
while the majority of pregabalin abuse-related ADE reports were for
young adult male patients.
Some MENA region countries did not report any gabapentinoids
ADE to FAERS. This may be attributed to variations in policies and
characteristics of reporting systems in the region because each country
has its adverse event reporting system. For example, Saudi Adverse
Event Reporting System (SAERS) was launched by SFDA in March 2009
to monitor the safety of post-marketed medications. Also, the Turkish
Pharmacovigilance Center (TUFAM) was established in 2015.42The
analysis also revealed that abuse-related ADEs were higher for pregabalin
than gabapentin. This result confirms the findings by Evoy et al. 2019.
Although this study did not assess the concomitant medications,
Table 1: Characteristics of Gabapentinoids Abuse-Related ADEs
Reported to FAERS (January 2008-June 2020).
Table 2: Type of Gabapentinoids Abuse-related ADE Reactions
Reported to FAERS (January 2008-June 2020).
ADE Reactions
Gabapentin
n (%)
Pregabalin
n (%)
69 (25.9%)
197 (74.1%)
-
77 (39.1%)
2 (2.9%)
24 (12.2%)
TOTAL
Drug Abuse
Overdose
Intentional Overdose
-
12 (6.1%)
Drug Dependence
4 (5.8%)
12 (6.1%)
Withdrawal Syndrome
8 (11.6%)
10 (5.1%)
Intentional Product Misuse
-
9 (4.6%)
Product Use in Unapproved Indication
16 (23.2%)
9 (4.6%)
Intoxication
14 (20.3%)
8 (4.1%)
Drug Tolerance
1 (1.4%)
6 (3.0%)
Euphoric Mood
1 (1.4%)
4 (2.0%)
-
4 (2.0%)
Maternal use of the illicit drug
8 (11.6%)
8 (4.1%)
Substance-Induced Psychotic Disorder
15 (21.7%)
14 (7.1%)
Loss of Personal Independence in Daily
Activities
*Multiple reactions were listed for some cases
Gabapentin
n (%)
Pregabalin
n (%)
Total
66 (32.2%)
139 (67.8%)
Male
11 (16.7%)
67 (48.2%)
Female
35 (53.0%)
37 (26.6%)
Reactions
Not Specified
20 (30.3%)
35 (25.2%)
TOTAL
Death
6 (9.1%)
4 (2.9%)
54.4
36.0
Hospitalization
8 (12.1%)
24 (17.3%)
50
28
Life-threatening
2 (3.0%)
-
Disability
1 (1.5%)
-
Characteristics
Age
Mean
Median
Standard Deviation
±16.5
±19.1
Table 3: Outcomes of Gabapentinoids Abuse-related ADE Reported to
FAERS (January 2008-June 2020).
Gabapentin events
n (%)
Pregabalin
events n (%)
66 (32.2%)
139 (67.8%)
Type
Congenital anomaly
-
2 (1.4%)
Expedited
46 (69.7%)
103 (74.1%)
3 (4.5%)
6 (4.3%)
63 (95.5%)
137 (98.6%)
Other serious outcomes
3 (4.5%)
2 (1.4%)
Non-serious outcomes
Consumer
11 (16.7%)
33 (23.7%)
Healthcare Professional
55 (83.3%)
106 (76.3%)
Non-Expedited
Source
MENA Region Countries (Includes Only Countries with FAERS Reports)
Algeria
-
7 (5.0%)
Bahrain
-
1 (0.7%)
Egypt
1 (1.5%)
3 (2.2%)
Iran
17 (25.8%)
1(0.7%)
Israel
2 (3.0%)
13 (9.4%)
Jordan
-
19 (13.7%)
Lebanon
2 (3.0%)
3 (2.2%)
Morocco
-
1 (0.7%)
2 (3.0%)
33 (23.7%)
Saudi Arabia
Tunisia
-
1 (0.7%)
Turkey
42 (63.6%)
55 (39.6%)
-
2 (1.4%)
United Arab Emirates
PTB Reports, Vol 7, Issue 1, Jan-Apr, 2021
Chiappini et al. 2016 and Evoy et al. 2019 studies found that most deaths
occurred in patients who were also taken opioids.29,39
This study has some limitations. First, there is no certainty that the ADE
reports were due to gabapentinoids themselves; it might be due to the
concomitant medications. Second, since ADE reporting from consumers
or healthcare professionals is voluntary, the FDA does not receive reports
for every adverse event or medication error that occurs with a product.
Therefore, FAERS data can detect safety signals but cannot be used to
estimate the incidence of adverse events or medication errors.
CONCLUSION
Over 200 cases of abuse-related gabapentinoids events were reported
to FEARS from the MENA region in the study period. Further
studies should assess risk factors and potential programs to reduce
gabapentinoids abuse.
ACKNOWLEDGEMENT
None
7
Alsheikh MY, et al.: Analysis of Gabapentinoids Abuse-Reports in the Middle East and North Africa Region
Declarations of interest
None
Funding
This research did not receive any specific grant from funding agencies in
the public, commercial, or not-for-profit sectors.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Ethical approval
This study does not involve the use of any human or animal subjects.
Data availability
The data used to support the findings of this study will be available upon
request.
Authors contributions
Mona Alsheikh: Writing- original draft preparation, methodology,
data curation. Ali Alshahrani: Software, reviewing, and editing. Reem
Almutairi: Conceptualization, reviewing, and editing. Hana Althobait:
Methodology, investigation. Validation. Ahmed Ibrahim Fathelrahman:
Editing and proofreading, Enrique Seoane-Vazquez: visualization,
supervision, and editing. Moudi Alasmari: Writing- original draft,
methodology, reviewing, and editing.
REFERENCES
1. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ-1 calcium
channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4(2):e00205.
2. Vadivelu N, Mitra S, Narayan D. Recent advances in postoperative pain
management. Yale J Biol Med. 2010;83(1):11-25.
3. Imani F, Rahimzadeh P. Gabapentinoids: Gabapentin and pregabalin for
postoperative pain management. Anesthesiol Pain Med. 2012;2(2):52-3.
4. Neurontin® [package insert]. Pfizer Inc. USA. 2020. http://labeling.pfizer.com/
ShowLabeling.aspx?format=PDF&id=630.
5. Lyrica® [package insert]. Pfizer Inc., USA. 2020. http://labeling.pfizer.com/
showlabeling.aspx?id=561.
6. Johansen ME. Gabapentinoid use in the United States 2002 through 2015.
JAMA Intern Med. 2018;178(2):292-4.
7. Urquhart L. Market Watch: Top drugs and companies by sales in 2017. Nat Rev
Drug Discov. 2018;17(4):232-3.
8. AlKhamees OA, AlNemer KA, Maneea MWB, AlSugair FA, AlEnizi BH, Alharf
AA. Top 10 most used drugs in the Kingdom of Saudi Arabia 2010–2015. Saudi
Pharm J. 2018;26(2):211-6.
9. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of
pregabalin: A systematic review and meta-analysis of randomized controlled
trials. Epilepsia. 2011;52(4):826-36.
10. Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and
Gabapentin. Drugs. 2017;77(4):403-26.
11. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler
J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol.
2013;69(12):2021-5.
12. Bodén R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin
dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol.
2014;70(2):197-204.
13. Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse and the US
opioid epidemic: The case for reclassification as a controlled substance and the
need for pharmacovigilance. Risk Manag Healthc Policy. 2018;11:109-16.
14. Alosaimi FD, Alruwais FS, Alanazi FA, Alabidi GA, Aljomah NA, Alsalameh NS.
Patient’s reasons for obtaining psychotropic medications without a prescription
at retail pharmacies in Central Saudi Arabia. Neurosciences. 2016;21(4):338-44.
15. Alblooshi H, Hulse GK, ElKashef A, AlHashmi H, Shawky M, AlGhaferi H, et
al. The pattern of substance use disorder in the United Arab Emirates in 2015:
Results of a National Rehabilitation Centre cohort study. Subst Abuse Treat Prev
Policy. 2016;11(1):19.
16. Al-Husseini A, Wazaify M, Hout MCV. Pregabalin Misuse and Abuse in
Jordan: A Qualitative Study of User Experiences. Int J Ment Health Addict.
2018;16(3):642-54.
8
17. Yargic I, Ozdemiroglu FA. Pregabalin abuse: A case report. Klin Psikofarmakol
Bul. 2011;21(1):64-6.
18. Aldemir E, Altintoprak AE, Coşkunol H. Pregabalin dependence: A case report.
Turk Psikiyatr Derg. 2015;26(3):217-20.
19. Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: A case report. Curr
Drug Saf. 2015;10(2):184-6.
20. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler
J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol.
2013;69(12):2021-5.
21. Saudi Food and Drug Authority (n.d.-a). 2020. Available at: https://www.sfda.
gov.sa/ar/drug/circulations/DocLib/%D8%A5%D8%AC%D8%B1%D8%A7%
D8%A1%D8%A7%D8%AA%20%D9%88%D8%B6%D9%88%D8%A7%D
8%A8%D8%B7%20%D8%B5%D8%B1%D9%81%20%D9%85%D8%B3
%D8%AA%D8%AD%D8%B6%D8%B1%D8%A7%D8%AA%20Pregabalin.
pdf.
22. Saudi Food and Drug Authority (n.d.-b). 2020. Available at: https://www.sfda.
gov.sa/ar/drug/drug_reg/DocLib/anti_drugs22.pdf.
23. Jordan Food and Drug Administration. Formal Statement About the restricted
Dispensing of Pregabalin in Jordan. JFDA. 2013. http://www.jfda.jo/
EchoBusV3.0/SystemAssets/2f00f42e-427b-40ba-abf4 93adfb8c2ad6.jpg.
24. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A
comparison of the pharmacokinetics and pharmacodynamics of pregabalin and
gabapentin. Clin Pharmacokinet. 2010;49(10):661-9.
25. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an
abuse liability for pregabalin-results from the Swedish spontaneous adverse
drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947-53.
26. Schifano F. Misuse and abuse of pregabalin and gabapentin: Cause for concern?.
CNS Drugs. 2014;28(6):491-6.
27. Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the
effect of methadone: A survey among substance misusers. Eur Addict Res.
2014;20(3):115-8.
28. Papazisis G, Tzachanis D. Pregabalin’s abuse potential: A mini-review focusing
on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52(8):709-916.
29. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin
and pregabalin abuse, misuse, dependence, or overdose: An analysis of the
Food and Drug Administration Adverse Events Reporting System (FAERS). Res
Soc Adm Pharm. 2019;15(8):953-8.
30. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions
current perspectives and future needs. J Am Med Assoc. 1999;281(9):824-9.
31. Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug
abuse - Proactive pharmacovigilance. N Engl J Med. 2018;379(3):205-7.
32. FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA, USA.
2019. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-eventreporting-system-faers/fda-adverse-event-reporting-system-faers-publicdashboard.
33. Fahed AC, El-Hage-Sleiman AKM, Farhat TI, Nemer GM. Diet, genetics, and
disease: A focus on the Middle East and North Africa region. J Nutr Metab.
2012.
34. Chemaitelly H, Mahmud S, Kouyoumjian SP, Al‐Kanaani Z, Hermez JG, Abu‐
Raddad LJ. Who to Test for Hepatitis C Virus in the Middle East and North
Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million
Tests. Hepatol Commun. 2019;3(3):325-39.
35. International Organization for Standardization. Popular standards. ISO, Geneva.
2019
36. Reports Received and Reports Entered into FAERS by Year. FDA. Published
2015. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-eventreporting-system-faers/reports-received-and-reports-entered-faers-year
37. Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C.
Pregabalin abuse and dependence in Germany: Results from a database query.
Eur J Clin Pharmacol. 2013;69(6):1335-42.
38. Bossard JB, Ponté C, Dupouy J, Lapeyre-Mestre M, Jouanjus E.
Disproportionality Analysis for the Assessment of Abuse and Dependence
Potential of Pregabalin in the French Pharmacovigilance Database. Clin Drug
Investig. 2016;36(9):735-42.
39. Chiappini S, Schifano F. A Decade of Gabapentinoid Misuse: An Analysis of the
European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database.
CNS Drugs. 2016;30(7):647-54.
40. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs)
for signal generation from spontaneous adverse drug reaction reports.
Harmacoepidemiol Drug Saf. 2001;10(6):483-6.
41. Wazaify M, Abood E, Tahaineh L, Albsoul-Younes A. Jordanian community
pharmacists’ experience regarding prescription and nonprescription drug abuse
and misuse in Jordan: An update. J Subst Use. 2017;22(5):463-8.
42. Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse
Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database
in the Context of the First Pharmacovigilance Legislation. Drugs: Real World
Outcomes. 2016;3(1):33-43.
PTB Reports, Vol 7, Issue 1, Jan-Apr, 2021